Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9958473 | 0.85 | PDE10A (0.35) | PDE10ADGAT1 | |
| SCHEMBL9958472 | 0.85 | PDE10A (0.35) | PDE10ADGAT1 | |
| SCHEMBL20752626 | 0.83 | — | — | |
| SCHEMBL9958551 | 0.82 | DGAT1 (0.52) | PDE10ADGAT1 | |
| SCHEMBL9959627 | 0.82 | DGAT1 (0.52) | PDE10ADGAT1 | |
| SCHEMBL1767786 | 0.82 | PDE10A (0.41) | PDE10ADGAT1KLKB1 | |
| SCHEMBL20531562 | 0.80 | DGAT1 (0.38) | PDE10ADGAT1KLKB1KDM4E | |
| SCHEMBL19780157 | 0.80 | DGAT1 (0.38) | PDE10ADGAT1KLKB1KDM4E | |
| SCHEMBL20531674 | 0.80 | DGAT1 (0.38) | PDE10ADGAT1KLKB1KDM4E | |
| SCHEMBL16203617 | 0.77 | ACHE (0.35) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | PDE10A 3182/4885DGAT1 2615/4885KLKB1 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.